Comparative Pharmacology
Head-to-head clinical analysis: MINOXIDIL EXTRA STRENGTH FOR MEN versus MINOXIDIL FOR WOMEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINOXIDIL EXTRA STRENGTH FOR MEN versus MINOXIDIL FOR WOMEN.
MINOXIDIL EXTRA STRENGTH (FOR MEN) vs MINOXIDIL (FOR WOMEN)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.
Minoxidil is a potassium channel opener. It activates ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arterioles, causing peripheral vasodilation and reduced blood pressure. For hair growth, the exact mechanism is unclear but involves increased cutaneous blood flow, stimulation of hair follicle proliferation via direct effects on dermal papilla cells, and prolongation of the anagen phase.
Topical: 1 mL of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 mL (100 mg).
Topical: 2% or 5% solution, 1 mL applied to the scalp twice daily (morning and evening).
None Documented
None Documented
Terminal elimination half-life is approximately 4.2 hours in patients with normal renal function. However, the pharmacodynamic half-life (duration of antihypertensive effect) is about 24 hours, allowing once-daily dosing.
Terminal elimination half-life: approximately 4.2 hours in patients with normal renal function; may extend to 24+ hours in renal impairment.
Primarily renal (approximately 95% as parent drug and metabolites). Biliary/fecal excretion is minimal (less than 5%).
Primarily renal (90% as unchanged drug and metabolites; 10% via feces via biliary elimination).
Category A/B
Category A/B
Vasodilator / Hair Growth Stimulant
Vasodilator / Hair Growth Stimulant